Pharmacy

AML: mutant IDH1 inhibitor HMS-101 2:51
AML: mutant IDH1 inhibitor HMS-101
Michael Heuser • 25 Oct 2019
MM: The battle for new drugs 1:18
MM: The battle for new drugs
Jonathan Keats • 13 Sep 2019
The need for academic and pharmaceutical collaboration in drug development 9:19
The need for academic and pharmaceutical collaboration in drug development
Jay Bradner et al.
Self-administration of bortezomib in multiple myeloma: results from Cardiff 2:18
Self-administration of bortezomib in multiple myeloma: results from Cardiff
Tanya Burton
Accelerating clinical trials in transplantation 2:24
Accelerating clinical trials in transplantation
Charles Craddock • 12 Oct 2018
Regulatory approval of CPX-351 for secondary AML 2:11
Regulatory approval of CPX-351 for secondary AML
Charles Craddock • 12 Oct 2018
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML 2:14
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
Simon Cheesman • 12 Oct 2018
The switch to biosimilar rituximab at UCH: 12 months on 0:54
The switch to biosimilar rituximab at UCH: 12 months on
Simon Cheesman • 12 Oct 2018
Patient education is important for drug tolerance and adherence 1:42
Patient education is important for drug tolerance and adherence
Jeanne McCarthy-Kaiser • 21 Mar 2018
The role of the pharmacist in transplant 1:52
The role of the pharmacist in transplant
Jeanne McCarthy-Kaiser • 21 Mar 2018
A pharmacoeconomic analysis of multiple myeloma treatment 3:17
A pharmacoeconomic analysis of multiple myeloma treatment
Rafael Fonseca • 1 Jun 2018
Value and cost in MM treatment 4:56
Value and cost in MM treatment
Vincent Rajkumar • 1 Jun 2018
Subcutaneous daratumumab: combining efficacy, safety & convenience 1:08
Subcutaneous daratumumab: combining efficacy, safety & convenience
Ajai Chari • 1 Jun 2018
Treating GvHD: current challenges and newly approved drugs 1:09
Treating GvHD: current challenges and newly approved drugs
Katie Gatwood • 21 Mar 2018
The importance of pharmacist intervention in the treatment of GvHD with ruxolitinib and ibrutinib 1:43
The importance of pharmacist intervention in the treatment of GvHD with ruxolitinib and ibrutinib
Katie Gatwood • 21 Mar 2018
Ruxolitinib and ibrutinib: the future for GvHD treatment? 2:29
Ruxolitinib and ibrutinib: the future for GvHD treatment?
Katie Gatwood • 21 Mar 2018
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals